158 related articles for article (PubMed ID: 29391906)
1. PERCIST in Perspective.
O JH; Wahl RL
Nucl Med Mol Imaging; 2018 Feb; 52(1):1-4. PubMed ID: 29391906
[TBL] [Abstract][Full Text] [Related]
2. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
[TBL] [Abstract][Full Text] [Related]
3. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using
Kitajima K; Watabe T; Nakajo M; Ishibashi M; Daisaki H; Soeda F; Tanemura A; Kanekura T; Yamazaki N; Ito K
Jpn J Radiol; 2022 Jan; 40(1):75-85. PubMed ID: 34287739
[TBL] [Abstract][Full Text] [Related]
4. The utility of
Kitajima K; Kawanaka Y; Komoto H; Minami T; Yokoi T; Kuribayashi K; Kijima T; Nakamura A; Hashimoto M; Kondo N; Hasegawa S; Yamakado K
Hell J Nucl Med; 2021; 24(3):186-198. PubMed ID: 34901959
[TBL] [Abstract][Full Text] [Related]
5. Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments.
Pinker K; Riedl C; Weber WA
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(Suppl 1):55-66. PubMed ID: 28361188
[TBL] [Abstract][Full Text] [Related]
6. Agreement Between the European Organization for Research and Treatment of Cancer and Positron Emission Tomography Response Criteria in Solid Tumors in Evaluating Treatment Response in Solid Malignant Tumors.
Nasir Z; Mahmood T; Adel H; Nausheen S; Hamid S; Sattar A; Manohar M
Cureus; 2019 Aug; 11(8):e5422. PubMed ID: 31632874
[TBL] [Abstract][Full Text] [Related]
7. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.
Wahl RL; Jacene H; Kasamon Y; Lodge MA
J Nucl Med; 2009 May; 50 Suppl 1(Suppl 1):122S-50S. PubMed ID: 19403881
[TBL] [Abstract][Full Text] [Related]
8. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
Skougaard K; Nielsen D; Jensen BV; Hendel HW
J Nucl Med; 2013 Jul; 54(7):1026-31. PubMed ID: 23572497
[TBL] [Abstract][Full Text] [Related]
9. Comparison Between
Rossi G; Bauckneht M; Genova C; Rijavec E; Biello F; Mennella S; Dal Bello MG; Cittadini G; Bruzzi P; Piva R; Ceriani V; Sambuceti G; Lopci E; Morbelli S; Grossi F
J Nucl Med; 2020 Jul; 61(7):990-998. PubMed ID: 31806768
[TBL] [Abstract][Full Text] [Related]
10. PET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST).
Ding Q; Cheng X; Yang L; Zhang Q; Chen J; Li T; Shi H
J Thorac Dis; 2014 Jun; 6(6):677-83. PubMed ID: 24976990
[TBL] [Abstract][Full Text] [Related]
11. Assessment of tumor response to neoadjuvant chemotherapy in patients with breast cancer using MRI and FDG-PET/CT-RECIST 1.1 vs. PERCIST 1.0.
Kitajima K; Miyoshi Y; Yamano T; Odawara S; Higuchi T; Yamakado K
Nagoya J Med Sci; 2018 May; 80(2):183-197. PubMed ID: 29915436
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of response to stereotactic body radiation therapy for nonsmall cell lung cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors.
Han J; Song Q; Guo F; Du R; Fang H; Kang J; Lu Z
Nucl Med Commun; 2022 Jun; 43(6):717-724. PubMed ID: 35354781
[TBL] [Abstract][Full Text] [Related]
13. Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0.
O JH; Lodge MA; Wahl RL
Radiology; 2016 Aug; 280(2):576-84. PubMed ID: 26909647
[TBL] [Abstract][Full Text] [Related]
14. Response Monitoring in Metastatic Breast Cancer: A Prospective Study Comparing
Vogsen M; Harbo F; Jakobsen NM; Nissen HJ; Dahlsgaard-Wallenius SE; Gerke O; Jensen JD; Asmussen JT; Jylling AMB; Braad PE; Vach W; Ewertz M; Hildebrandt MG
J Nucl Med; 2023 Mar; 64(3):355-361. PubMed ID: 36207136
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of response to neoadjuvant chemotherapy for esophageal cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors.
Yanagawa M; Tatsumi M; Miyata H; Morii E; Tomiyama N; Watabe T; Isohashi K; Kato H; Shimosegawa E; Yamasaki M; Mori M; Doki Y; Hatazawa J
J Nucl Med; 2012 Jun; 53(6):872-80. PubMed ID: 22582049
[TBL] [Abstract][Full Text] [Related]
16. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
Shang J; Ling X; Zhang L; Tang Y; Xiao Z; Cheng Y; Guo B; Gong J; Huang L; Xu H
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1945-53. PubMed ID: 27236466
[TBL] [Abstract][Full Text] [Related]
17. An evaluation of the response to neoadjuvant chemotherapy for osteosarcoma of extremities: PERCIST versus RECIST 1.1 criteria after long-term follow-up.
Xu J; Li Y; Xie L; Sun X; Cai Z; Wang S; Wang Q; Sun K; Guo W
Ann Nucl Med; 2022 Jun; 36(6):553-561. PubMed ID: 35380350
[TBL] [Abstract][Full Text] [Related]
18. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.
Minamimoto R; Fayad L; Advani R; Vose J; Macapinlac H; Meza J; Hankins J; Mottaghy F; Juweid M; Quon A
Radiology; 2016 Jul; 280(1):220-9. PubMed ID: 26854705
[TBL] [Abstract][Full Text] [Related]
19. TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib.
Ho KC; Fang YD; Chung HW; Liu YC; Chang JW; Hou MM; Yang CT; Cheng NM; Su TP; Yen TC
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2155-2165. PubMed ID: 27260520
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of
Yokose T; Kitago M; Matsusaka Y; Masugi Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Endo Y; Toyama K; Iwabuchi Y; Takemura R; Ishii R; Nakahara T; Okuda S; Jinzaki M; Kitagawa Y
Cancer Med; 2020 Jun; 9(12):4059-4068. PubMed ID: 32281301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
